eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


1/2021
vol. 46
 
Share:
Share:
more
 
 
abstract:
Clinical immunology

Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia

Milos Kostic
1
,
Tanja Dzopalic
1
,
Goran Marjanovic
1, 2
,
Ivana Urosevic
3, 4
,
Ivana Milosevic
3, 4

1.
Department of Immunology, Medical Faculty of Nis, University of Nis, Nis, Serbia
2.
Department of Hematology and Clinical Immunology, Clinical Centre Nis, Nis, Serbia
3.
Department of Hematology, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
4.
Clinical Centre of Vojvodina, Hematology Clinic, Novi Sad, Serbia
Cent Eur J Immunol 2021; 46 (1): 54-62
Online publish date: 2021/04/18
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Galectin-1 (Gal-1) has been implicated in the progression of chronic lymphocytic leukemia (CLL) but also the development of immunodeficiency, which commonly accompany this malignancy. In this in vitro study, we investigated the effects of Gal-1 inhibition in the sera of immunocompromised CLL patients on immunomodulating properties of dendritic cells (DCs). DCs derived from peripheral blood mononuclear cells were treated with a healthy serum, CLL serum as well as the combination of CLL serum and Gal-1 inhibitor (OTX008). Following the treatment, the expression levels of DC maturation markers (CD80, CD83, CD86 and IDO-1) were determined as well as their cytokine profile and the ability to polarize the immune response in co-cultures with CD4+ T cells. After treatment with CLL serum, an increase in interleukin (IL)-10 production was observed in both DC cultures and co-cultures with CD4+ T cells. OTX008 caused a reduction in IL-10 production as well as IL-2, but no significant alteration in the expression of DC maturation markers or T regulatory cell (Treg) frequency was observed. The results of our study suggest that Gal-1 from CLL serum give rise to a specific IL-10+ CD4+ T cell phenotype, other than Treg, that could mediate immunodeficiency development in CLL patients.
keywords:

galectin-1, immunodeficiency, chronic lymphocytic leukemia, OTX008, dendritic cell

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe